In SCCHN, miR-193b acts as an oncogene through its action on NF1, and in pancreatic cancer, it acts as a tumor suppressor by directly targeting KRAS through AKT, ERK, and MAPK pathways [207]. Here, KRAS is linked to pancreatic neoplasm.